Updates on Heart Valve Diseases: Personalized Treatment and Management

Dear Colleagues,

Heart valve disease represents a major health problem, and heart valve replacement is considered to be the gold standard treatment. Although there is a large portfolio of heart valve substitutes currently available, none of them fulfil the aims required to make an ideal heart valve substitute, which are to mimic the characteristics of a normal native heart valve, be durable, have effective hemodynamics, and be biocompatible.

Actually, for many patients, the vast majority of available devices are adequate, but there are some patients that may benefit more from a specific device. In elderly patients and in those deemed to be at high risk for surgery, TAVI is definitely preferred over conventional surgery. Conversely, in intermediate and low-risk patients, the choice is somehow more difficult. Preoperative risk scores, such as EuroSCORE and the STS score, may be helpful. However, the abovementioned scores only predict early outcomes. In order to optimize treatment, we have to also analyze the long-term outcome. Only in this way we can achieve patient-based treatment.

To fill this gap, we invite authors to submit original and review articles that explore how a personalized patient-targeted treatment can solve, or rather not solve, heart valve disease.

Dr. Chiara Tessari
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• heart valve disease
• congenital heart valve disease
• transcatheter valve implantation/replacement
• surgical technique
• device technology
• tissue engineering
• structural valve deterioration
• device failure/success